Did you know?

Apellis Pharmaceuticals (NASDAQ:APLS) Insider Buying and Selling Activity. Current Insider Ownership Percentage 7.50%. Number Of Insiders Buying (Last 12 Months) 0. Number Of Insiders Selling (Last 12 Months) 13. Amount Of Insider Selling (Last 12 Months) $35.44 M. Get APLS Insider Trade Alerts. Want to know when executives …View today's Apellis Pharmaceuticals Inc stock price and latest APLS news and analysis. Create real-time notifications to follow any changes in the live ...Noteworthy Wednesday Option Activity: RUN, APLS, VRT. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sunrun Inc (Symbol: RUN), where a ...Funds + ETFs. After-Hours Quotes. See All Market Activity->. News + Insights.

3 дня назад ... The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags.Over the past 3 months, 21 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with ...Wall Street Analysts Predict a 51.91% Upside in Apellis Pharmaceuticals, Inc. (APLS): Here's What You Should Know. (Zacks) Oct-25-23 07:00AM. Apellis …Apellis Pharmaceuticals, Inc. (APLS). NASDAQ: APLS · IEX Real-Time Price · USD.WALTHAM, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...

As of Q1 2023, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) was the most commonly held stock out of the 12 stocks with biggest upside potential according to analysts. Its shares were held by 42 of ...Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved t... ….

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Nasdaq apls. Possible cause: Not clear nasdaq apls.

The latest price target for Apellis Pharmaceuticals ( NASDAQ: APLS) was reported by Goldman Sachs on Thursday, November 9, 2023. The analyst firm set a price target for 74.00 expecting APLS to ...APLS U.S.: Nasdaq Apellis Pharmaceuticals Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 28, 2023 7:01 p.m. EST Delayed quote $ 46.50 -0.66 -1.40% After Hours Volume: 1...Analyst Price Forecast Suggests 203.86% Upside. As of July 6, 2023, the average one-year price target for Apellis Pharmaceuticals is 104.04. The forecasts range from a low of 76.76 to a high of ...

Oct 20, 2023 · WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The Lancet published the positive 24-month results from the Phase 3 OAKS and ... Apellis pharmaceuticals, inc. (nasdaq:apls) saw its share price drive 177% higher over five years. Shareholders gained a total return of 0.7% in the last quarter. Apellis pharmaceuticals made a loss in the past year, but has seen revenue growth of 43% per year. The company has a good track record of growing its revenue at a compound rate of 23% ... CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...

lillium stock Market Activity -> Funds + ETFs After-Hours Quotes See All Market Activity-> News + Insights See All News + Insights-> -> Apellis Pharmaceuticals, Inc. Common Stock P/E & …WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ... best option trading platformsralph lauren revenue Apellis Pharmaceuticals, Inc. (“Apellis”) (NASDAQ:APLS) recently completed an upsized underwritten public offering of 8563830 shares of its common stock at ...WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its third quarter 2021 ... best trading course The average twelve-month price prediction for Apellis Pharmaceuticals is $66.50 with a high price target of $93.00 and a low price target of $29.00. Learn more on APLS's analyst rating history. Do Wall Street analysts like Apellis Pharmaceuticals more than its competitors? array techwells fargo bank refinancetrade desk stock forecast 2025 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) develops innovative treatments for diseases with unmet needs. In 2023, the FDA approved Syfovre, the only treatment for geographic atrophy (GA), a ...Advertisement. Apellis Pharmaceuticals Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View APLS financial statements in full. dental plans in massachusetts value. Forecast 12 Month Forward PEG Ratio. -0.44. Investors are always looking for companies with good growth prospects selling at attractive prices. One popular statistic used to identify such ... Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) released its quarterly earnings results on Wednesday, November, 1st. The company reported ($1.17) earnings per share for the quarter, missing analysts' … 1971 kennedy half dollars valueslyv stocktower reits Apellis Pharmaceuticals (NASDAQ:APLS) dropped 10% amid a new short report. The short report is apparently from Favus research, according to traders on Wednesday. Details of the short report couldn ...9,367,396. 841,461. 11.1323. Back to APLS Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid ...